Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Impact · against what's priced in

Protalix provides positive Phase 1 PK/PD data for PRX-115, demonstrating that a 36 mg dose can maintain uric acid levels below target for up to 12 weeks. While this supports a competitive dosing advantage in the Phase 2 RELEASE study, the stock is likely to remain stagnant until top-line results emerge in H2 2027.

PLX+0.40

No priced-in read yet